Market Intelligence, Clinical Progress, and High-Purity Reagents for Dermatology & Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IGFL1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IGFL1 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation & Disulfide Bonding). |
View IGFL1 Products |
| Receptor Complex | IGFLR1 ECD-Fc Fusion Protein Critical for binding assays and neutralizing antibody screening. |
View IGFLR1 Products |
| Gene Delivery | IGFL1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View IGFL1 Products |
| Benchmark Ab | Anti-IGFL1 Neutralizing Reference Recombinant positive control. Sequence Verified. |
View IGFL1 Products |
| Validator | IGFL1 siRNA Set For knockdown verification. |
View IGFL1 Products |
| Related Target: IGFLR1 | Primary receptor for IGFL1; essential for ligand-blocking assays. | View IGFLR1 Products |
| Related Target: IGF1R | Core IGF-axis receptor; synergistic pathway for combination screening. | View IGF1R Products |
| Related Target: IGF1 | Closest structural homolog; essential for selectivity counter-screening. | View IGF1 Products |
| Related Target: IGFL2 | Family member with compensatory signaling potential. Critical for selectivity screening. | View IGFL2 Products |
| Related Target: IL-17A | Synergistic inflammatory pathway in psoriasis and dermatological conditions. | View IL-17A Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| IGF Family Homology Cross-Reactivity | IGFL1, IGF1, IGF2, IGFL2, IGFL3 ortholog panel. Sequence verified. >95% purity. Endotoxin controlled. |
| Lack of Species-Reactive Controls | Human / Mouse / Cyno IGFL1 proteins available for cross-species lead selection. |
| Lack of Cellular Controls | IGFL1 Lentivirus & siRNA for overexpression / knockdown specificity checks. |
| False Positives in Binding Assays | Endotoxin <1 EU/ug to minimize non-specific TLR activation. Theoretical MW confirmed. |
| Proper Disulfide Bond Formation | HEK293 expressed proteins with native mammalian folding machinery. MW verified by Mass Spec. |
| ECM Binding Interference | High-concentration protein batches (>1mg/mL) for matrix-binding assays and dermal equivalent penetration studies. |
| Receptor-Mediated Internalization (for ADC) | IGFLR1 overexpression lentivirus for constructing internalization-positive cell lines. |
Live IGFL1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Resistance & Pathway Research
- ➤ Latest Dermatology Research
- ➤ Melanoma & Oncology Publications
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for IGFL1-targeted therapeutics is accelerating at the preclinical/clinical interface. IGFL1 (Insulin-like Growth Factor-Like Family Member 1) is heavily upregulated in psoriatic lesions and specific tumor microenvironments, signaling through its specific receptor IGFLR1. Unlike traditional growth factor targets, the IGFL1/IGFLR1 axis offers a cleaner target profile than the promiscuous IGF1R pathway. Biotech innovators are exploring dual pathways in regenerative dermatology (agonist approaches for alopecia and wound healing) and oncology (antagonist modalities for melanoma and squamous cell carcinoma). As first-generation antibody and siRNA candidates enter IND-enabling studies, the next wave of R&D is targeting receptor blockade, combination regimens with IGF-axis inhibitors, and biomarker-driven patient selection. The emergence of drug resistance and loss of efficacy in established therapies (e.g., IL-17/IL-23 inhibitors) further opens opportunities for IGFL1 as a second-line or combination therapy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Neutralizing Antibody (Monoclonal) | Emerging Biotechs, Academic Consortia | Solid tumors (melanoma, NSCLC), Psoriasis, Atopic Dermatitis | Ligand-receptor blockade (Need high-purity IGFL1 + IGFLR1 ECD pair) |
| Recombinant Protein (Agonist) | Regenerative Medicine Companies | Alopecia, Wound Healing | Dermal Papilla Cell Proliferation Assay (Need bioactive, properly folded protein) |
| Decoy / Trap Fusion (Fc Fusion) | Preclinical Programs | Solid tumors, Inflammation | Affinity Measurement (Need Sequence Verified ECD) |
| siRNA / Antisense | Early-stage Discovery, Dermatology Biotech | Fibrosis, Inflammatory Dermatology, Hyperproliferative Skin | Knockdown validation (Need validated IGFL1 siRNA & lentivirus) |
| Peptide Mimetic | Academic Labs (Translation) | Atopic Dermatitis | Solid-Phase Binding Kinetics (Need IGFLR1 ECD-Fc fusion) |
| Small Molecule | Academic & Pharma | Refractory Autoimmune | Selectivity Assay (Need homolog proteins to prevent off-target effects) |
Related Targets for Cross-Selling
- IGFLR1: Primary receptor for IGFL1; essential for ligand-blocking and neutralizing assays.
- IGF1R: Core IGF-axis receptor; synergistic pathway for combination screening.
- IGF1: Closest structural homolog; mandatory for selectivity counter-screening.
- IGFL2: Family member with compensatory signaling potential; critical for selectivity profiling.
- IL-17A: Synergistic inflammatory pathway in psoriasis; useful for comparative and combination studies.